「dom」の検索結果

Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.

日本語の概要は準備中です。原文の説明を表示しています。

Plot per-group distributions of continuous data using boxplots, violins, beeswarms, quasirandom jitter, and raincloud plots with sample-size honesty (Weissgerber 2015), KDE-bandwidth awareness, and N-aware encoding choices. Use when comparing distributions across a small number of groups — expression per cluster, biomarker per arm, scores per condition — and the bar-of-mean default is misleading.

日本語の概要は準備中です。原文の説明を表示しています。

Handles batch effects in bulk RNA-seq via design-matrix inclusion (the correct path for DE), ComBat/ComBat-seq for visualization, SVA for unknown latent factors, RUVSeq for negative-control-gene-anchored unwanted variation, and limma::removeBatchEffect for plotting only. Encodes the Nygaard 2016 cardinal sin against testing on a batch-corrected matrix, the choice between SVA/RUVg/RUVs/RUVr, the confounding non-identifiability problem, the single-cell boundary (Harmony/MNN are NOT for bulk), and the Goh 2017 harmonization critique. Use when designing a DE analysis with batch structure, troubleshooting batch-dominated PCA, choosing ComBat vs ComBat-seq, handling unknown batch via SVA, integrating across studies, or deciding when (rarely) to subtract batch.

日本語の概要は準備中です。原文の説明を表示しています。

Cross-method decision tree for calling hits in pooled CRISPR screens. Catalogs statistical models (MAGeCK RRA, MAGeCK MLE, BAGEL2, drugZ, JACKS, Chronos, CERES), experimental designs each is built for, failure modes outside design domain, reconciliation when methods disagree, multiple-testing and effect-size thresholds, the order of operations (count -> QC -> CN-correct -> hit-call -> validate), the second-best-sgRNA conservative rule, and consensus-hit strategy. Use when choosing among MAGeCK / BAGEL2 / drugZ / JACKS / Chronos for a given design, reconciling disagreement across two or three methods on the same screen, deciding whether to require consensus, gating downstream validation by hit-confidence tier, or interpreting unstable hit lists across reruns.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Identifies super-enhancers from H3K27ac, MED1, or BRD4 ChIP-seq using ROSE, ROSE2, LILY, HOMER -style super, and ENCODE dELS cross-referencing. Handles peak stitching parameters, ranking choices, hockey-stick inflection, marker choice (H3K27ac vs MED1/BRD4), and cross-condition comparison with spike-in normalization. Constructs core regulatory circuitry (Saint-Andre 2016) from SE-encoded TFs. Use when identifying cell-identity / cancer-associated regulatory domains, comparing super-enhancers between conditions, identifying master transcription factor networks, or predicting BET-inhibitor responsiveness.

日本語の概要は準備中です。原文の説明を表示しています。

Reads, validates, and prepares CDISC SDTM and ADaM clinical trial data for analysis. Covers SDTM domain joins (DM, AE, EX, VS, LB, DS), ADaM architecture (ADSL, BDS, OCCDS, ADTTE) with traceability, treatment-emergent AE conventions, baseline derivation, SUPPQUAL/NSV handling, Define-XML 2.1, and Pinnacle 21 / CORE validation. Use when working with clinical trial datasets in CDISC SDTM/ADaM format, preparing analysis-ready data, or validating for regulatory submission.

日本語の概要は準備中です。原文の説明を表示しています。

Predicts ADMET properties using ADMETlab 3.0 (119 platform features, including 77 prediction models with modeled-endpoint uncertainty), ADMET-AI, DeepChem MolNet, and chemprop D-MPNN with explicit handling of OECD QSAR principles, applicability domain assessment, calibration, hERG/CYP/AMES endpoints, and PAINS / Lipinski / Ro5 / Veber / BBB druglikeness filters. Use when filtering compounds for drug-likeness, prioritizing leads by predicted safety, or building an in-house ADMET QSAR model.

日本語の概要は準備中です。原文の説明を表示しています。

Performs gene-level association from GWAS summary statistics via genetically predicted tissue expression using FUSION, PrediXcan, S-PrediXcan, S-MultiXcan, UTMOST, MOSTWAS, kTWAS, EpiXcan, TIGAR-V2, and probabilistic fine-mapping with FOCUS and MA-FOCUS. Use when running TWAS from GWAS sumstats, prioritising candidate causal genes from a GWAS lead locus, picking single-tissue vs cross-tissue models, identifying LD-induced TWAS false positives, choosing ancestry-matched prediction weights, fine-mapping co-regulated TWAS hits, or triangulating TWAS with cis-eQTL Mendelian randomization and colocalization to nominate a causal gene.

日本語の概要は準備中です。原文の説明を表示しています。

Runs cis-pQTL Mendelian randomization for drug-target validation using UKB-PPP (Olink), deCODE (SomaScan), Fenland, INTERVAL, ARIC, and FinnGen-PPP proteomes plus colocalization triangulation, phenome-wide on-target adverse-effect scans, cross-platform Olink/SomaScan replication, and PAV (protein-altering variant) sensitivity. Use when nominating or de-risking a drug target from plasma-proteome GWAS, mimicking pharmacological inhibition via cis-pQTL instruments, separating shared-causal from LD-confounded signal under the Schmidt 2020 cis-MR framework, screening on-target adverse phenotypes pheWAS-style, or producing publication-grade STROBE-MR plus PP.H4 evidence for a target gene.

日本語の概要は準備中です。原文の説明を表示しています。

Create and use BAI/CSI indices for BAM/CRAM files using samtools and pysam. Use when enabling random access to alignment files or fetching specific genomic regions.

日本語の概要は準備中です。原文の説明を表示しています。

Detect and adjust for horizontal pleiotropy in two-sample Mendelian randomization by distinguishing uncorrelated (UHP) from correlated (CHP) pleiotropy and choosing among Egger, MR-PRESSO, MR-RAPS, CAUSE, LHC-MR, LCV, MR-Clust, MR-Mix, and contamination-mixture methods. Use when validating an MR causal claim, running the STROBE-MR sensitivity battery, suspecting a shared heritable confounder, working under weak-instrument or polygenic-exposure regimes, or reconciling discordant estimates across robust methods.

日本語の概要は準備中です。原文の説明を表示しています。

Analyzes differential transcript usage (DTU) and isoform switches with functional consequence prediction (NMD via 50nt rule, ORF disruption, protein domain loss/gain, signal peptide changes, IDR alterations, coding-potential shifts). Tools include IsoformSwitchAnalyzeR v2 (auto-selects satuRn for >5 reps else DEXSeq), the manual DRIMSeq -> DEXSeq/satuRn -> stageR DTU pipeline, and fishpond/swish for inferential-uncertainty-aware DTE. Distinguishes DTU from DGE and DTE; integrates external annotators (CPC2, Pfam, SignalP, IUPred2A or DeepTMHMM). Use when investigating how splicing differences alter protein function or trigger NMD-mediated degradation.

日本語の概要は準備中です。原文の説明を表示しています。

Three modes for CS-conference papers (CVPR/ICCV/ECCV vision, ACL/EMNLP/NAACL NLP, ICLR/NeurIPS/ICML/AAAI ML). DIRECT-EDIT mode (common): the user describes a change in Chinese or English and the manuscript (LaTeX or Markdown) is edited directly through a CS-venue writing toolkit with author sign-off (use for 改这段 / 把中文想法写成 latex / polish / de-AI / translate / compress a passage). REVIEW mode (occasional, pre-submission): harden the paper through an adversarial courtroom review engine (N holistic domain reviewers / contestability routing / two-sided trial / three-way verdict / clerk-converged multi-round loop) with consensus-gated, author-signed revisions (use for review / critique / 审稿 / 评审 / mock-review). AUTO mode (unattended, opt-in via /goal): run the review-revise loop toward a verifiable goal, applying safe fixes under a drift-bounded policy and queueing risky ones. Resolves all inputs at runtime, no hardcoded paths. Not a from-scratch drafter (use ml-paper-writing) and not an official-venue rebuttal.

日本語の概要は準備中です。原文の説明を表示しています。

Use when the user wants a comprehensive project-wide audit, full health check, or scan across all domains.

日本語の概要は準備中です。原文の説明を表示しています。

Access Core Motion accelerometer, gyroscope, magnetometer, device-motion, pedometer, activity-recognition, altitude, headphone motion, batched high-frequency workout motion, and water-submersion/depth data. Use when reading device sensors, counting steps, detecting walking/running/driving/cycling, tracking altitude, building motion interactions, handling AirPods head tracking, or implementing watchOS dive/depth features.

日本語の概要は準備中です。原文の説明を表示しています。

This skill should be used when the user asks to "deploy with OpenShip", "manage a self-hosted OpenShip instance", "debug an OpenShip deployment", or manage its domains, storage, backups, or upgrades through the CLI.

日本語の概要は準備中です。原文の説明を表示しています。

This skill should be used when user asks to "deploy with Dokploy", "use Dokploy Cloud", "manage self-hosted Dokploy", "deploy Docker Compose on Dokploy", "manage Dokploy databases", "configure Dokploy domains", or "look up Dokploy CLI commands".

日本語の概要は準備中です。原文の説明を表示しています。

Design and implement adaptive filters using DSP System Toolbox System objects. Use when working with adaptive filtering, system identification, noise cancellation, echo cancellation, active noise control (ANC), channel equalization, inverse system identification, or adaptive prediction. Covers dsp.LMSFilter, dsp.RLSFilter, dsp.FilteredXLMSFilter, dsp.FrequencyDomainAdaptiveFilter, dsp.AffineProjectionFilter, dsp.BlockLMSFilter, dsp.AdaptiveLatticeFilter, dsp.FastTransversalFilter, maxstep(), and algorithm selection for adaptive filtering problems. Replaces deprecated adaptfilt.* objects (removed R2020a).

日本語の概要は準備中です。原文の説明を表示しています。

Speed up local parfor, parfeval, or spmd by switching to a thread-based parallel pool. Trigger when a user describes slow or disappointing local parallel performance, even if they don't mention threads. Symptoms: parfor on a laptop/workstation is slower than expected or "only slightly faster than for"; parfor scales poorly with the number of workers; ticBytes/tocBytes, the Parallel Pool dashboard, mpiprofile, or system tools show large per-worker data transfer; large broadcast variables or sliced inputs make iterations slow; opening a process pool dominates a short workload; user mentions serialisation or data transfer overhead. Also trigger on any question about whether code or a function works on a thread pool. For non-pool MATLAB performance work (vectorisation, preallocation, profiling), defer to matlab-optimize-performance.

日本語の概要は準備中です。原文の説明を表示しています。

Analyze AMS waveform data using Mixed-Signal Blockset utilities: phase noise measurement, clock jitter, anti-aliased resampling, timing measurements, lock time, INL/DNL, ADC/DAC calibration, HSpice import. Use when analyzing time-domain voltage from PLL/VCO/clock simulations, measuring phase noise from variable-step solver output, computing jitter, or resampling non-uniform data.

日本語の概要は準備中です。原文の説明を表示しています。

Unified skill for all MATLAB and Simulink report generation tasks. Covers report generation, PDF report, document generation, mlreportgen, Report Generator, template, TitlePage, Chapter, multipage HTML, HTMLPage, html-multipage, custom reporter, customizeReporter, template hole, page header, page border, company style package, branded reporters, buildTemplates, Simulink report, model documentation, slreportgen, block diagram report, model report, subsystem documentation, SystemDiagramFinder, SystemIO, ExecutionOrder, LookupTable, template style, page footer, TemplateSrc, report package, table variants, multiple HTML pages, PDF report generation, Word report, DOM API, FormalTable, BaseTable, Figure, FormalImage, Section.

日本語の概要は準備中です。原文の説明を表示しています。

Use when engineering or selecting the best features for single-response classification or regression in MATLAB, whatever the data's modality — for non-tabular data it routes extraction to a domain skill, then selects, assesses, and delivers on the resulting table. Not for multi-response problems, model training, or raw data acquisition.

日本語の概要は準備中です。原文の説明を表示しています。

Build Simulink models that co-simulate with Eclipse SUMO traffic simulator. Use when creating SUMO-Simulink co-simulation, traffic simulation, TraCI connection, vehicle-in-the-loop testing, or ADAS scenario validation with SUMO. Covers Server/Client setup, Reader/Writer/Actor block configuration, random traffic generation, ego vehicle control, and SUMO file creation. Also use when the user mentions SumoInterfaceLibrary, .sumocfg files, or wants to connect Simulink to an external traffic simulator.

日本語の概要は準備中です。原文の説明を表示しています。